Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced ...
- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and ...
HORSHAM, Pa., Oct. 13, 2015 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (NASDAQ:MELA), a medical ...
